title: Combined CD34 positive plus CD2 negative selection for effective T-cell depletion as GvHD-prophylaxis in HLA-nonidentical blood progenitor cell transplantation.
abstract: G-CSF mobilized, T-cell-depleted peripheral blood progenitor cells (PBPC) and T-cell-depleted bone marrow (BM) were given to seven children (6 AL, 1 SCID) to prevent severe graft-versus-host-disease (GvHD) as well as graft rejection after transplantation from HLA-nonidentical parental donors. BM was T-cell-depleted by lectin agglutination and E-rosetting. For T-cell-depletion of the PBPC grafts a combination of CD34+ selection with the Ceprate SC immunoadsorption system and a subsequent depletion of CD2+ cells with immunomagnetic Dynabeads was used. The overall recovery was 0.3 (0.1-1.2)% for nucleated cells, 29 (18-45)% for CD3+ cells, respectively. The purity of CD34+ cells was 87 (68-97)% with a 0.3(0.05-0.7)% residual CD3+ T-cell contamination. In spite of the large T-cell number in the PBPC grafts the combination of CD34 positive and subsequent CD2 negative selection achieved a more than 4 log T-cell depletion and prevents severe GvHD even in HLA-nonidentical transplantation. In addition, if a high dose of progenitor cells ensures stable engraftment, this new approach could increase the possibility of wider use of HLA-mismatched family donors for transplantation.
authors.affiliation: Department of Transfusion Medicine, Red Cross Blood Center, Ulm, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Wiesneth
authors.forename: T
authors.initials: T
authors.lastname: Schreiner
authors.forename: W
authors.initials: W
authors.lastname: Friedrich
authors.forename: S
authors.initials: S
authors.lastname: Müller
authors.forename: B
authors.initials: B
authors.lastname: Maccari
authors.forename: E
authors.initials: E
authors.lastname: Erne
authors.forename: C
authors.initials: C
authors.lastname: Bischof
authors.forename: B
authors.initials: B
authors.lastname: Kubanek
mesh_terms: D000328:Adult; D018952:Antigens, CD34; D018801:CD2 Antigens; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006650:Histocompatibility Testing; D006801:Humans; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous